Table 3.
Trabectedin exposure.
| Treatment Delivery | Modified Intent-to-Treat Set (mITT); n = 128 | |
|---|---|---|
| Number of cycles received per patient |
Median (range) | 4 (1–44) |
| <6 cycles | 76 (59.4%) | |
| ≥6 cycles | 52 (40.6%) | |
| Dose reductions (per patient) | 0 cycle | 62 (48.4%) |
| 1 cycle | 17 (13.3%) | |
| 2 cycles | 21 (16.4%) | |
| >2 cycles | 18 (14.1%) | |
| Unknown 1 | 10 (7.8%) | |
| Cycle delays (per patient) | 0 cycle | 49 (38.3%) |
| 1 cycle | 22 (17.2%) | |
| 2 cycles | 8 (6.3%) | |
| >2 cycles | 44 (34.4%) | |
| Unknown 1 | 5 (3.9%) | |
Data shown are numbers and percentages of patients or median and range values with available data. 1 Patients who started the treatment with trabectedin before the signed informed consents and with unknown starting dose.